Adaptimmune Therapeutics PLC — Director's Dealing 2019

May 18, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2019-05-16

Reporting Person: Noble James (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-16	Ordinary Shares with a nominal value of GBP0.001 per share	M	1773100	$0.143	Acquired	1773100	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares with a nominal value of GBP0.001 per share	12945700	Direct

Footnotes

F1: The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person.

F2: The price reported in Column 4 of $0.143 per ordinary share is derived from the option purchase price paid on May 16, 2019 of GBP 0.112 per ordinary share.

F3: The 12,945,700 ordinary shares reported in Column 5 include 1,773,100 ordinary shares reported in Column 4 as well as 9,972,600 ordinary shares held by the Reporting Person and 1,200,000 ordinary shares that are represented by 200,000 ADSs held by the Reporting Person. Each ADS represents six ordinary shares of the Issuer. The ordinary shares reported in Column 5 represent solely the ordinary shares beneficially owned by the Reporting Person. Additionally, the Reporting Person holds options covering an aggregate of 12,722,376 ordinary shares of the Issuer.